These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 27282763)

  • 41. Coil closure of residual shunt after Amplatzer PFO occlusion.
    Meier B
    Catheter Cardiovasc Interv; 2011 Apr; 77(5):720-1. PubMed ID: 20939039
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Transcranial Doppler quantification of residual shunt after percutaneous patent foramen ovale closure. Comparison of two devices.
    Sorensen SG; Aguilar H; McKnight WK; Thomas H; Muhlestein JB
    J Interv Cardiol; 2010 Dec; 23(6):575-80. PubMed ID: 20796165
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Percutaneous PFO closure with Amplatzer PFO occluder: predictors of residual shunts at 6 months follow-up.
    Greutmann M; Greutmann-Yantiri M; Kretschmar O; Senn O; Roffi M; Jenni R; Luescher TF; Eberli FR
    Congenit Heart Dis; 2009; 4(4):252-7. PubMed ID: 19664027
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk and fate of residual interatrial shunting after transcatheter closure of patent foramen ovale: a long term follow up study.
    Hammerstingl C; Bauriedel B; Stüsser C; Momcilovic D; Tuleta I; Nickenig G; Skowasch D
    Eur J Med Res; 2011 Jan; 16(1):13-9. PubMed ID: 21345765
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Transcatheter closure of patent foramen ovale associated with atrial septal aneurysm with Amplatzer Cribriform septal occluder.
    Musto C; Cifarelli A; Pandolfi C; De Felice F; Fiorilli R; Caferri G; Violini R
    J Invasive Cardiol; 2009 Jun; 21(6):290-3. PubMed ID: 19494408
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Percutaneous closure of patent foramen ovale in cryptogenic embolism.
    Meier B; Kalesan B; Mattle HP; Khattab AA; Hildick-Smith D; Dudek D; Andersen G; Ibrahim R; Schuler G; Walton AS; Wahl A; Windecker S; Jüni P;
    N Engl J Med; 2013 Mar; 368(12):1083-91. PubMed ID: 23514285
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Late results after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism using the amplatzer PFO occluder without intraprocedural echocardiography: effect of device size.
    Wahl A; Tai T; Praz F; Schwerzmann M; Seiler C; Nedeltchev K; Windecker S; Mattle HP; Meier B
    JACC Cardiovasc Interv; 2009 Feb; 2(2):116-23. PubMed ID: 19463412
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical Performance of the New Gore Septal Occluder in Patent Foramen Ovale Closure: A Single-Center Experience.
    Sganzerla P; Rondi M; Pavone A; Aiolfi E; Facchinetti A; Funaro A; Negrini P
    J Invasive Cardiol; 2015 Sep; 27(9):430-4. PubMed ID: 26332878
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Safety and efficacy of left atrial appendage closure combined with patent foramen ovale closure for atrial fibrillation patients with patent foramen ovale].
    Zhao ZH; Song X; Wang SH; Luo J; Wu YB; Zhu Q; Fang M; Huan Q; Zhang XG; Tian B; Gu W; Zhu LN; Hao SW; Ning ZP
    Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Mar; 50(3):257-262. PubMed ID: 35340144
    [No Abstract]   [Full Text] [Related]  

  • 50. Propensity Score-Based Analysis of Percutaneous Closure Versus Medical Therapy in Patients With Cryptogenic Stroke and Patent Foramen Ovale: The IPSYS Registry (Italian Project on Stroke in Young Adults).
    Pezzini A; Grassi M; Lodigiani C; Patella R; Gandolfo C; Zini A; DeLodovici ML; Paciaroni M; Del Sette M; Toriello A; Musolino R; Calabrò RS; Bovi P; Adami A; Silvestrelli G; Sessa M; Cavallini A; Marcheselli S; Marco Bonifati D; Checcarelli N; Tancredi L; Chiti A; Del Zotto E; Tomelleri G; Spalloni A; Giorli E; Costa P; Giacalone G; Ferrazzi P; Poli L; Morotti A; Piras V; Rasura M; Simone AM; Gamba M; Cerrato P; Zedde ML; Micieli G; Melis M; Massucco D; Guido D; De Giuli V; Bonaiti S; D'Amore C; La Starza S; Iacoviello L; Padovani A;
    Circ Cardiovasc Interv; 2016 Sep; 9(9):. PubMed ID: 27582111
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Percutaneous implantation of a second device in patients with residual right-to-left shunt after patent foramen ovale closure.
    Rovera C; Biasco L; Orzan F; Belli R; Omedè P; Gaita F
    J Interv Cardiol; 2014 Dec; 27(6):548-54. PubMed ID: 25421752
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A propensity score-matched comparison between Cardia and Amplatzer PFO closure devices - insights from the SOLUTION registry (Swiss percutaneOus patent foramen ovale cLosUre in recurrent clinical events prevenTION).
    Puricel S; Arroyo D; Goy JJ; Praz F; Palhais N; Wahl A; Stauffer JC; Togni M; Berger A; Meier B; Cook S
    EuroIntervention; 2015 Jun; 11(2):230-7. PubMed ID: 24830681
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Importance of Persistent Right-to-Left Shunt After Patent Foramen Ovale Closure in Cryptogenic Stroke Patients.
    He L; Cheng G; Du Y; Zhang Y
    Tex Heart Inst J; 2020 Aug; 47(4):244-249. PubMed ID: 33472221
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Percutaneous patent foramen ovale closure: outcomes with the Premere and Amplatzer devices.
    Bissessor N; Wong AW; Hourigan LA; Jayasinghe RS; Scalia GS; Burstow DJ; Griffiths LR; Savage M; Walters DL
    Cardiovasc Revasc Med; 2011; 12(3):164-169. PubMed ID: 21640934
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Microtransesophageal Echocardiographic Guidance during Percutaneous Interatrial Septal Closure without General Anaesthesia.
    Snijder RJR; Renes LE; Swaans MJ; Suttorp MJ; Ten Berg JM; Post MC
    J Interv Cardiol; 2020; 2020():1462140. PubMed ID: 32982607
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Transseptal technique of percutaneous PFO closure results in persistent interatrial shunting.
    Tande AJ; Knickelbine T; Chavez I; Mooney MR; Poulose A; Harris KM
    Catheter Cardiovasc Interv; 2005 Jun; 65(2):295-300. PubMed ID: 15880797
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Is routine ultrasound guidance really necessary for closure of patent foramen ovale using the Amplatzer PFO occluder?
    Fateh-Moghadam S; Steeg M; Dietz R; Bocksch W
    Catheter Cardiovasc Interv; 2009 Feb; 73(3):361-6. PubMed ID: 19133676
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Patent foramen ovale closure with the Intrasept occluder: Complete 6-56 months follow-up of 247 patients after presumed paradoxical embolism.
    Spies C; Timmermanns I; Reissmann U; van Essen J; Schräder R
    Catheter Cardiovasc Interv; 2008 Feb; 71(3):390-5. PubMed ID: 18288745
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Occlutech percutaneous patent foramen ovale closure: Safety and efficacy registry (OPPOSE).
    Hildick-Smith D; Williams T; MacCarthy P; Melikian N; Monaghan M; Spence M; MacDonald ST; Duke A; Kovac J; McGregor A; Hilling-Smith R; Gomes A; Thomson C; Mullen M; Morrison L
    Int J Cardiol; 2017 Oct; 245():99-104. PubMed ID: 28778466
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Comparison on the efficacy and safety of different occlusion devices for the treatment of patients with patent foramen ovale].
    Liu WJ; Zhang YS; Cheng GS; Du YJ; He L; Wang XY; He XM
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Jun; 45(6):485-490. PubMed ID: 28648024
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.